Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring ...

MISSISSAUGA, ON, Oct. 2, 2025 /CNW/ - Kye Pharmaceuticals ("Kye") announced today that Health Canada has approved AGAMREE® (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD) in boys a ...

Every movement we make, whether walking, speaking or even breathing, depends on the health of our muscles and nerves. For people living with one of the more than 300 rare conditions known as ...

Dyne will also present encore data on zeleciment rostudirsen (z-rostudirsen, formerly known as DYNE-251, aninvestigational medicine being evaluated for the treatment of individuals with DMD mutations ...

The Oswestry Model uses a "traffic light system" to help neuromuscular teams identify key stages in a patient's journey in ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

See why Scholar Rock Holding Corporation remains a Strong Buy despite regulatory setbacks, with key catalysts ahead and ...

GeneDx CEO Katherine Stueland explains how her company screens babies’ DNA for mutations that cause thousands of treatable ...

Health Secretary Robert F. Kennedy Jr. is working on policy changes to the Vaccine Injury Compensation Program that would ...

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the first European participants have been randomized in ...

Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year ...